clevudine

Also Known As:

1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione,; 1-(2-deoxy-2-fluoro-beta-L-arabinofuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione; 1-(2-fluoro-2-deoxy-beta-D-arabinofuranosyl)thymine; 1-(2-fluoro-2-deoxy-beta-arabinofuranosyl)thymine; 1-(2-fluoro-5-methyl-beta,L-arabinofuranosyl)uracil; 1-(2-fluoro-beta-L-arabinofuranosyl)thymine; 2'-deoxy-2'-fluoroarabinofuranosylthymine; 2'-fluoro-5-methyl-1-beta-D-arabinofuranosyluracil; 2'-fluoro-5-methylarabinosyluracil; 2'-fluoro-5-methylarabinosyluracil, 2-(14)C-labeled; 5-methyl-2'-fluoroarauracil; D-FMAU; FMAU; L-FMAU

Networked: 114 relevant articles (10 outcomes, 31 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Yoo, Byung Chul: 9 articles (07/2014 - 07/2004)
2.	Alauddin, Mian M: 7 articles (01/2018 - 04/2002)
3.	Byun, Kwan Soo: 7 articles (07/2014 - 05/2006)
4.	Lee, Hyo-Suk: 7 articles (01/2012 - 07/2004)
5.	Shields, Anthony F: 6 articles (12/2017 - 01/2005)
6.	Paik, Seung Woon: 6 articles (03/2013 - 05/2006)
7.	Kim, Ju Hyun: 6 articles (01/2013 - 05/2007)
8.	Chung, Young-Hwa: 5 articles (03/2011 - 05/2006)
9.	Han, Joon-Yeol: 5 articles (03/2011 - 05/2006)
10.	Lee, Kwan Sik: 5 articles (03/2011 - 01/2007)

Related Diseases

1.	Chronic Hepatitis B 01/01/2010 - "The objectives of this study were to evaluate the safety and efficacy of a 1-year treatment with clevudine in chronic hepatitis B patients. " 12/01/2010 - "Efficacy of initial treatment with clevudine in naive patients with chronic hepatitis B." 06/01/2008 - "Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis B." 07/01/2004 - "A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B." 01/15/2017 - "Management of Clevudine-Resistant Chronic Hepatitis B: A Multicenter Cohort Study."
2.	Muscular Diseases (Myopathy) 01/01/2020 - "By selectively delivering the 5'-monophosphate to the liver, while retaining the unique anti-HBV activity of the 5'-triphosphate, ATI-2173 may provide an improved pharmacokinetic profile for clinical use, reducing systemic exposure of clevudine and potentially eliminating skeletal myopathy." 01/01/2022 - "Clevudine, a first-generation ASPIN, demonstrated potent and prolonged HBV suppression in phase 2 and 3 clinical studies, but long-term treatment was associated with reversible myopathy in a small number of patients. " 06/01/2009 - "Our study was aimed to analyze the clinical and pathological features of patients with clevudine-induced myopathy with some consideration of its pathogenetic mechanism. " 01/01/2020 - "However, long-term clevudine treatment was found to exhibit reversible skeletal myopathy in a small subset of patients and was subsequently discontinued from development. " 11/01/2017 - "The 95 patients with clevudine-induced myopathy comprised 52 women and 43 men aged 48.9 years (27-76 years). "
3.	Hepatitis B 01/15/2017 - "Data are lacking regarding the management of chronic hepatitis B (CHB) with resistance to clevudine (CLV). " 06/01/2010 - "Hepatitis B was reactivated with a flare-up, and a M204I mutation (YIDD mutant type) appeared with a higher viral load at 9 months after clevudine treatment. " 06/01/2010 - "Clevudine (30 mg once daily) was administered for recurrent hepatitis B. " 05/01/2009 - "Clevudine for hepatitis B." 06/01/2008 - "To characterize pharmacokinetic and pharmacodynamic profile of clevudine, a potent hepatitis B polymerase inhibitor. "
4.	Neoplasms (Cancer) 11/01/2013 - "After tumor size reached 150 ± 50 mm(3) (day 0), lipo-VNB (5mg/kg) was intravenously administered on days 0, 3 and 6. To monitor the therapeutic efficacy of lipo-VNB, [(18)F]FMAU PET was employed to evaluate the proliferation rate of tumor, and it was compared with that observed from [(18)F]FDG/[(18)F]fluoroacetate PET. " 11/01/2013 - "Previous studies have shown that the accumulation level of FMAU in tumor is proportional to its proliferation rate. " 05/01/2004 - "We performed pharmacokinetic measurements with [(14)C]FMAU and PET studies with [(11)C]FMAU using rats bearing several different syngeneic tumors. " 01/01/1985 - "We have conducted a phase I trial of FMAU in 17 patients with advanced cancer. " 11/01/2016 - "The model provides quantitative, mechanistic insights into the bioactivation of FAU and retention of FMAU in normal and tumor tissues and has potential utility to predict tumor responsiveness to FAU treatment."
5.	Sarcoma (Soft Tissue Sarcoma) 11/01/2013 - "Monitoring tumor response with [18F]FMAU in a sarcoma-bearing mouse model after liposomal vinorelbine treatment." 11/01/2013 - "This study demonstrated that 2'-deoxy-2'-[(18)F]fluoro-β-d-arabinofuranosyluracil ([(18)F]FMAU) is a promising PET probe for noninvasively monitoring the therapeutic efficacy of 6% PEGylated liposomal vinorelbine (lipo-VNB) in a subcutaneous murine NG4TL4 sarcoma mouse model. "

Related Drugs and Biologics

1.	Antiviral Agents (Antivirals)
2.	entecavir
3.	Hepatitis B e Antigens
4.	Lamivudine (Epivir)
5.	Telbivudine
6.	adefovir
7.	Emtricitabine (Emtriva)
8.	Arabinofuranosyluracil (Ara U)
9.	Vinorelbine (Navelbine)
10.	DNA (Deoxyribonucleic Acid)

Related Therapies and Procedures

1.	Therapeutics
2.	Oral Administration
3.	Kidney Transplantation
4.	Stents
5.	Intravenous Infusions